Which Cannabinoid Is Best for Inflammation?

CBD is the most extensively studied cannabinoid for inflammation, but it is not categorically the best. A systematic review of animal studies found that CBD, cannabigerol (CBG), and a CBD-plus-THC combination all consistently lowered key inflammatory markers, while THC alone did not. The honest answer is that the “best” cannabinoid depends on the type of inflammation, the tissue involved, and what evidence you’re willing to accept, since nearly all of the data comes from cell and animal studies rather than human trials. The landscape is more interesting than a single winner, though, and the lesser-known cannabinoids are catching up fast.

CBD Has the Deepest Evidence Base

CBD’s anti-inflammatory reputation rests on a body of preclinical research that dwarfs what exists for any other cannabinoid. One of its central mechanisms involves suppressing the NF-κB pathway, which acts as a master switch for genes that drive inflammation. In a study using brain immune cells stimulated with a bacterial toxin, CBD reduced NF-κB activity while THC did not.¹ That distinction matters: THC and CBD are often lumped together as “cannabis compounds,” but their effects on immune signaling can go in different directions.

A systematic review pulling together animal studies on cannabinoids and cytokines found that CBD consistently lowered levels of TNF-alpha, IL-1β, IL-6, and interferon-gamma, all major pro-inflammatory signals. CBG performed similarly. THC on its own, however, did not reliably reduce these markers.² This is a useful finding because many people assume THC must be anti-inflammatory since cannabis in general has that reputation. The evidence suggests CBD and CBG are doing most of that work.

CBD also works through pathways beyond the classical cannabinoid receptors. It does not strongly activate CB1 or CB2, yet it still dampens inflammation by engaging other molecular targets. That broad-spectrum activity is part of why it keeps showing up as effective across very different inflammation models, from joint tissue to brain immune cells to skin.

CBG Is the Strongest Contender for Gut Inflammation

Cannabigerol gets called the “mother cannabinoid” because it is the chemical precursor from which other cannabinoids form in the plant. But its anti-inflammatory profile is impressive in its own right, particularly for the digestive system. In a mouse model of inflammatory bowel disease, CBG reduced colon weight, lowered the enzyme myeloperoxidase (a marker of neutrophil-driven inflammation), normalized levels of both pro- and anti-inflammatory cytokines, and cut nitric oxide production in immune cells. The researchers concluded CBG could be a candidate for clinical testing in IBD patients.³

More recent work strengthens the case. A 2024 study in rats on a high-fat, high-sugar diet found that CBG decreased the expression of several enzymes involved in producing inflammatory lipid compounds in the colon, including COX-1, COX-2, and 12/15-LOX.⁴ And in a separate colitis model, a high-CBG hemp extract dramatically reduced disease severity, preserved colon length (colitis typically shortens it), and decreased tissue damage.⁵

CBG also activates the CB2 receptor with intermediate strength, which CBD largely does not. In a study using inflamed human gum tissue cells, CBG and the less-known cannabinoid CBDV (cannabidivarin) both activated CB2 and suppressed prostaglandin E2 production, a lipid compound that drives pain and swelling. CBD did not activate CB2 at all in the same experiment.⁶ This matters because CB2 receptors sit mainly on immune cells, and activating them generally dials down the inflammatory response.⁷

When CBD and CBG Were Tested Head to Head

Surprisingly few studies have directly compared cannabinoids against each other. One that did looked at airway inflammation in mice given a bacterial endotoxin. Both CBD and CBG, when formulated with a solubilizing agent, reduced the flood of neutrophils into the lungs by roughly 50 to 65 percent. They were in the same ballpark. But combining them at a one-to-one ratio did not produce any additional benefit; the combination actually failed to significantly reduce neutrophil recruitment at all.⁸ That result is a reminder that “more cannabinoids” does not automatically mean “better.” The assumption that combining compounds always enhances the effect is popular in the cannabis world, but the pharmacology can work against you.

Another comparison comes from a pain and inflammation study in rats. A full-spectrum cannabis extract and a CBG isolate both prevented a rise in TNF-alpha in the spinal cord and blood after an inflammatory challenge. The full-spectrum extract produced sustained pain relief earlier (by day 10), while CBG isolate took longer but eventually fully restored normal pain sensitivity by day 15.⁹ The takeaway is that both worked, but the timing and trajectory differed, which could matter depending on whether someone needs fast relief or long-term management.

The Minor Cannabinoids With Emerging Evidence

Beyond CBD and CBG, a handful of less abundant cannabinoids are generating early interest. Cannabichromene (CBC), tetrahydrocannabivarin (THCV), and cannabinol (CBN) were tested in human immune cells and all three dampened the NLRP3 inflammasome, a molecular complex that acts as a key trigger for the inflammatory cascade. THCV and CBC also suppressed the IL-6 signaling pathway, which drives chronic inflammation in conditions from rheumatoid arthritis to metabolic disease.¹⁰

These findings are very early. There are no animal models, let alone human trials, confirming that CBC, THCV, or CBN have meaningful anti-inflammatory effects in a living body at doses that are realistic. Still, the fact that they target the inflammasome is worth noting, because inflammasome-driven inflammation is central to conditions like gout, certain types of liver disease, and some neurological disorders. If the cell-culture findings hold up, these minor cannabinoids could eventually be tailored to very specific types of inflammation.

The dose-response patterns also vary between cannabinoids. Research on sensory neurons found that CBD produces a straightforward linear dose response (more CBD, more effect), while CBG and CBC follow a steeper sigmoidal curve, and CBN has an inverted U-shaped pattern where moderate doses activate neurons but higher doses do not.¹¹ This means the “right” dose of one cannabinoid could be completely wrong for another, and simply taking more is not always better.

Raw Cannabinoids and Why CBDA Deserves Attention

Fresh cannabis plants do not actually contain much CBD or THC. What they produce are the acidic precursors: CBDA and THCA. These get converted into their better-known forms through heat (smoking, vaping, cooking). But the acidic versions have their own biological activity, and for inflammation specifically, CBDA may be underappreciated.

CBDA selectively inhibits COX-2, the same enzyme targeted by drugs like ibuprofen and celecoxib. In lab testing, CBDA blocked COX-2 with about nine times greater selectivity than COX-1, which is a favorable ratio because COX-1 helps protect the stomach lining and you generally want to leave it alone. Meanwhile, THCA was a far weaker COX-2 inhibitor.¹² A broader review of acidic cannabinoids found anti-inflammatory actions mediated through multiple targets, including serotonin receptors, TRP channels, and the nuclear receptor PPARγ.¹³

This is worth knowing for anyone juicing raw cannabis or using products that have not been heated. The CBDA in those preparations is not just an inactive precursor waiting to become CBD; it has its own anti-inflammatory mechanism that could be complementary. The challenge is that CBDA is unstable and converts to CBD even at room temperature over time, making it harder to formulate and dose consistently.

Beta-Caryophyllene, the Cannabinoid Hiding in Your Spice Rack

Not all cannabinoids come from cannabis. Beta-caryophyllene (BCP) is a terpene found in black pepper, cloves, oregano, and many other plants, including cannabis. It was identified as the first dietary cannabinoid because it selectively binds to the CB2 receptor and functions as a full agonist there.¹⁴ In mice, oral BCP at modest doses strongly reduced carrageenan-induced inflammation, and this effect vanished in mice that had been engineered to lack CB2 receptors, confirming the mechanism.¹⁴

BCP also activates PPARs, nuclear receptors involved in regulating metabolism and inflammation.¹⁵ It is non-psychoactive and already consumed widely as a food ingredient, which sidesteps many regulatory and safety hurdles that restrict cannabis-derived cannabinoids. If you’re looking for a CB2-targeted anti-inflammatory compound with a known safety profile, BCP is the most accessible option available right now.

Where Different Cannabinoids Shine by Condition

The type of inflammation changes which cannabinoid looks most promising. Here is how the preclinical evidence breaks down by tissue and disease:

Gut inflammation: CBG has the most targeted evidence, with multiple colitis models showing tissue protection, reduced damage scores, and normalized cytokine levels. Activation of both CB1 and CB2 receptors has been shown to improve intestinal inflammation, reduce pain sensitivity in the gut, and control diarrhea in mouse colitis models.¹⁶
Joint inflammation: CBD blocked the progression of collagen-induced arthritis in mice when given after symptoms had already started, protecting joint tissue from severe damage.¹⁷
Brain inflammation: CBD and synthetic cannabinoid receptor agonists reduced microglial activation (the brain’s inflammatory response) both in cell culture and in a mouse model relevant to Alzheimer’s disease. Three weeks of treatment prevented cognitive impairment and lowered inflammatory gene expression.¹⁸
Skin inflammation: CBD has early preclinical support for eczema, psoriasis, and general inflammatory skin conditions, but confirmed clinical results are still missing. Early-phase human studies have shown improvements in itching and lesion severity, though the evidence remains preliminary.¹⁹²⁰
Airway inflammation: Both CBD and CBG reduced neutrophil infiltration in lung tissue by over 50 percent in a mouse model of acute airway inflammation.⁸

None of this should be read as medical advice. These are animal and cell studies. But the pattern is useful: CBG keeps appearing in gut-related research, CBD dominates joint and neuroinflammation work, and airway inflammation responds to both.

Boosting Your Own Endocannabinoids

Your body already produces cannabinoids: anandamide (AEA) and 2-AG. These endocannabinoids are anti-inflammatory, but they get broken down quickly by two enzymes. Blocking those enzymes is a different strategy for reducing inflammation through the cannabinoid system without taking plant cannabinoids at all.

In a mouse model of airway inflammation, inhibitors of both breakdown enzymes reduced TNF-alpha levels whether given by injection or applied directly to the lungs. The enzyme that breaks down anandamide (FAAH) and the one that breaks down 2-AG (MAGL) were both effective targets, suggesting that raising your own endocannabinoid levels can provide protection against inflammation and airway overreactivity.²¹ These enzyme inhibitors are not commercially available as supplements, but exercise, omega-3 fatty acids, and certain dietary compounds are thought to modestly increase endocannabinoid tone through natural means. The research on pharmaceutical endocannabinoid-boosting drugs is ongoing and may eventually offer another option for people who want cannabinoid-system benefits without consuming cannabis.

Bioavailability Is a Practical Bottleneck

A cannabinoid that looks powerful in a petri dish may not do much when swallowed, because cannabinoids as a class are poorly absorbed when taken orally. They are extremely fat-soluble, which means they get trapped in gut tissue and broken down by the liver before much reaches the bloodstream. This has driven research into alternative delivery routes, including transdermal patches, nasal sprays, and mucosal absorption (under the tongue or inside the cheek).²²

This is relevant when comparing cannabinoids because the delivery method can matter as much as which compound you choose. The airway study that compared CBD and CBG, for instance, only saw significant results when the cannabinoids were formulated with a solubilizing agent; without it, oral dosing was ineffective.⁸ If you are using a cannabinoid for anti-inflammatory purposes and not seeing results, the formulation could be the problem rather than the molecule itself. Products designed for better absorption, such as nanoemulsions or lipid-based carriers, may deliver meaningfully different amounts to the bloodstream than a basic oil tincture.

The Gap Between Preclinical Promise and Clinical Proof

Almost everything described above comes from cells in a dish or mice in a lab. The leap to confirmed effects in people has been rocky. A 2025 systematic review and meta-analysis that specifically examined human clinical studies of CBD and THC on inflammatory biomarkers described the results as “inconsistent but biologically plausible.” The preclinical mechanisms are clear, but converting those into strong, reproducible changes in human blood markers has been limited by differences in dosing, formulation, and the populations studied.²³

This is the sobering context behind any claim about cannabinoids and inflammation. The lab evidence is real and points in a consistent direction: these compounds interact with immune signaling in ways that generally push toward less inflammation. But “reduces TNF-alpha in mouse spleen tissue” and “helps your knee pain” are separated by a wide gap that, for most cannabinoids, has not been bridged with rigorous human data.

Sex Differences in Cannabinoid Response

An underappreciated complication is that cannabinoid receptors do not behave identically in everyone. Research on brain immune cells found that the CB1 receptor controls sickness behavior differently in males and females.²⁴ This is a single finding from one study, but it aligns with broader observations across pharmacology that hormones, receptor density, and enzyme activity differ by sex and can alter how drugs work. It also means that a cannabinoid dose or formulation that works well for one person may not translate directly to another, and future clinical research will need to account for this variability if it wants to produce recommendations worth trusting.

For anyone currently navigating the supplement aisle or dispensary menu wondering which cannabinoid to try for inflammation, the practical reality is this: CBD has the most research behind it and is widely available. CBG is worth watching closely, especially for digestive inflammation, and is increasingly available in hemp-derived products. The minor cannabinoids and acidic forms are scientifically interesting but too early in their research arc to recommend over the better-studied options. And formulation, whether you are absorbing the compound effectively, may matter just as much as which compound you pick.